

*Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**石四藥集團有限公司**  
**SSY Group Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

**UNAUDITED OPERATING RESULTS**  
**FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2018**

This announcement is made by SSY Group Limited (the “Company”) pursuant to Inside Information Provisions (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”)) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2) of the Listing Rules.

The board of directors (the “Board”) of the Company is pleased to announce the following unaudited operating results of the Company and its subsidiaries (together, the “Group”) for the nine months ended 30 September 2018 based on its management accounts which have not been audited or reviewed by the auditor of the Company.

As a result of the increases in sales volumes and average selling prices of intravenous infusion (“IV”) solution, the unaudited turnover of the Group for the nine months ended 30 September 2018 increased by 46% as compared with the same period of 2017 to approximately HK\$3,073 million. The unaudited gross profit of the Group for the nine months ended 30 September 2018 was approximately HK\$1,905 million, representing an increase of 64% as compared with the same period of 2017. The unaudited gross profit margin of the Group for the nine months ended 30 September 2018 was approximately 62.0%, representing a rise of 6.9 percentage point from 55.1% for the same period of 2017. For the nine months ended 30 September 2018, the Group’s unaudited profit attributable to the shareholders of the Company (the “Shareholders”) increased by 42% as compared with the same period of 2017 to approximately HK\$647 million.

Among the abovementioned unaudited turnover of the Group, the unaudited sales of IV solution (including the subcontracting products) for the nine months ended 30 September 2018 increased by 45% as compared with the same period of 2017 to approximately HK\$2,746 million, which is comprised of the following:

<b>For the nine months ended 30 September 2018</b>	<b>Unaudited sales (HK\$)</b>	<b>Increase from same period of 2017</b>	<b>% of unaudited sales of IV solution</b>
Non-PVC soft bag IV solution	1,338 million	28%	48.7%
Upright soft bag IV solution	478 million	90%	17.4%
PP plastic bottle IV solution	595 million	46%	21.7%
Glass bottle IV solution	335 million	75%	12.2%

**Shareholders and potential investors should note that all financial information contained in this announcement is unaudited. Accordingly, such information shall in no way be regarded as to provide any indication of the audited financial results of the Group for the nine months ended 30 September 2018 or any assurance on such audited financial results. Such information may differ from the information to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of compiling such operating results information.**

**Shareholders and potential investors are advised to exercise caution in dealing in the securities of the Company.**

On behalf of the Board  
**Chow Hing Yeung**  
*Company Secretary*

Hong Kong, 18 October 2018

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.*